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Abstract 
The efficacy of Fusobacterium necrophorum crude leukotoxoid vaccine to immunize and protect steers 
against experimentally induced liver abscesses was evaluated. The vaccine consisted of cell-free culture 
supernatant of a high leukotoxin-producing strain of F. necrophorum, inactivated with formalin and 
homogenized with an oil emulsion adjuvant. Vaccine was injected subcutaneously on days 0 and 21. 
Blood samples were collected weekly to monitor immune response. Three weeks after the second 
vaccination, steers were injected intraportally with F. necrophorum culture to induce liver abscesses. 
Three weeks later (day 63), steers were euthanatized and necropsied; livers were examined, and 
protection was assessed. Anti-leukotoxin antibody titers in the control steers generally did not differ from 
the baseline (week 0) titers. The titers in the vaccinated groups increased, more so after the second 
injection, and the increase was generally dose dependent. At necropsy, all steers in the control group had 
liver abscesses. In the vaccinated groups, two out of five steers in the 1.0 ml group and one each in the 
2.0, 5.0, and 2.25 ml (concentrated) groups had liver abscesses. The difference suggests a protective 
effect of antileukotoxin antibodies against experimentally induced liver abscesses. 
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Summary
The efficacy of Fusobacterium
necrophorum crude leukotoxoid vaccine to
immunize and protect steers against experi-
mentally induced liver abscesses was evalu-
ated. The vaccine consisted of cell-free
culture supernatant of a high leukotoxin-
producing strain of F. necrophorum, inacti-
vated with formalin and homogenized with an
oil emulsion adjuvant. Vaccine was injected
subcutaneously on days 0 and 21. Blood
samples were collected weekly to monitor
immune response. Three weeks after the
second vaccination, steers were injected
intraportally with F. necrophorum culture to
induce liver abscesses. Three weeks later (day
63), steers were euthanatized and necropsied;
livers were examined, and protection was
assessed. Anti-leukotoxin antibody titers in
the control steers generally did not differ
from the baseline (week 0) titers. The titers
in the vaccinated groups increased, more so
after the second injection, and the increase
was generally dose dependent. At necropsy,
all steers in the control group had liver
abscesses. In the vaccinated groups, two out
of five steers in the 1.0 ml group and one
each in the 2.0, 5.0, and 2.25 ml (concen-
trated) groups had liver abscesses. The differ-
ence suggests a protective effect of anti-
leukotoxin antibodies against experimentally
induced liver abscesses.




Liver abscesses are of economic concern
to the feedlot industry because they cause
liver condemnation, reduced feed efficiency,
and reduced weight gain. Fusobacterium
necrophorum, is the primary causative agent
of liver abscesses. The incidence of liver
abscesses averages 18 to 32% in feedlot
cattle and is related to feeding high grain
diets. Rapid ruminal fermentation of grain in
the rumen results in ruminal acidosis and
rumenitis, which are considered to be predis-
posing factors for liver abscesses.
Fusobacterium necrophorum, a normal
inhabitant of the rumen, colonizes the ruminal
epithelial wall, reaches the liver via the portal
circulation, and sets up infection. The ability
of F. necrophorum to colonize ruminal epi-
thelium and establish infection in the liver is
attributed mainly to a potent leukotoxin that
is toxic to leukocytes, macrophages, ruminal
epithelial cells, and hepatocytes. Therefore,
immunizing the animal against the toxin may
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prevent the onset of liver abscesses. Our The leukotoxin concentration in the
objective was to determine the efficacy of F. original culture supernatant was 27,020
necrophorum leukotoxoid vaccine to immu- units/ml. In the culture supernatant concen-
nize steers and to provide protection against trated 5.2-fold, the leukotoxin concentration
experimentally induced liver abscesses. was 54,040 units/ml. Apparently, the process
Experimental Procedures
Fusobacterium necrophorum, A25, a leukotoxin concentration in the 4.5 ml dose.
high leukotoxin producing strain, previously
isolated from a liver abscess was used to Antibody titers in the control steers in-
prepare the vaccine, which consisted of cell- jected with phosphate-buffered saline gener-
free supernatant (original or concentrated ally did not differ from the baseline through-
5.2 fold) inactivated by adding formalin and out the 6-week sampling period. The titers in
homogenized with an oil emulsion adjuvant. the vaccinated steers increased (P<.01) fol-
The leukotoxicity of the original and concen- lowing the first vaccination and increased
trated culture supernatants, before and after much more after the second injection (Figure
formalin inactivation, was determined. 1). A significant treatment x week interac-
Twenty-five Holstein steers (mean body body titers appeared to be related to the dose
weight 860 lb), fed ad libitum a diet of alfalfa of leukotoxoid, with the 1.0 ml dose eliciting
hay, were assigned randomly to five groups: the lowest antibody titers and the 5.0 ml dose
control; three doses (1.0, 2.0, and 5.0 ml) of eliciting the highest. The purpose of using the
the culture supernatant; and a dose of the concentrated supernatant was to determine
concentrated supernatant (2.25 ml) equiva- whether concentrating the culture supernatant
lent to the leukotoxin concentration in 4.5 ml to reduce the injection volume would alter its
of the original culture supernatant (Table 1). immunogenicity or protective effect. Appar-
Each steer in the control group received 4.5 ently, concentrating the culture supernatant
ml of phosphate buffer saline mixed with reduced its immunogenicity as evidenced by
adjuvant. All injections were given subcuta- lower antibody titers.
neously on days 0 and 21.
Jugular blood samples were collected at group had liver abscesses as compared to two
weekly intervals after the first vaccination to out of five steers in the 1.0-ml-vaccinated
monitor the immune response. Serum sam- group and one each in the 2.0, 5.0, and 2.25
ples were assayed for anti-leukotoxin anti- ml (concentrated) groups (Table 2). Based
body titers. Three weeks after the second on Fisher’s exact test (2-tail), the incidence of
vaccination, steers were inoculated intra- liver abscesses was lower (P<0.01) in the
portally by an ultrasound-guided, percut- vaccinated groups (all four doses) than in the
aneous, catheterization procedure with F. control. Steers that developed abscesses
necrophorum to induce liver abscesses (n=10) had lower anti-leukotoxin titers
Steers were euthanatized 21 days after the (P<0.05) during wk 1 to 6 than those steers
intraportal challenge and examined for ab- 
scesses and other gross lesions in the liver 
and other organs.
Results and Discussion
of concentration reduced the leukotoxin
activity. Therefore, 2.25 ml of the concen-
trated supernatant was used to equal the
tion (P < .01) occurred. Generally, the anti-
At necropsy, all five steers in the control
(n=15) that did not develop abscesses in the
liver, regardless of the treatment (Figure 2).
degree of protection against experimentally
induced liver abscesses. However, further
Our results indicate that F. necrophorum
studies are required to determine the efficacy
culture supernatant was capable’ of eliciting
of the vaccine in feedlot cattle with naturally
developing liver abscesses.
anti-leukotoxin immunity that provided some
Table 1. Treatment Groups and Leukotoxin Concentration in the Culture
Supernatant
Culture Concentrated Phosphate Leukotoxin
Treatment
Control
Supernatant Supernatanta Buffered- Adjuvant Titer per
(ml) (ml) Saline (ml) (ml) Dose
— — 4.5 .5 —
Culture
supernatant, 1.0 ml
0.9 — .l 24,318
Culture
supernatant, 2.0 ml
1.8 — .2 48,636
Culture
supernatant, 5.0 ml
4.5 — .5 121,590
Concentrated
supernatant, 2.25 ml
2.25 2.25 .5 121,590
a Culture supernatant concentrated 5.2-fold
Table 2. Experimental Induction of Liver Abscesses in Control or Vaccinated Steers
Liver Abscesses
Treatment No. of Steers Necropsya Incidence (%)
Control 5 5/5 100
Culture supernatant, 1.0 ml 5 2/5 40
Culture supernatant, 2.0 ml 5 1/5 20
Culture supernatant, 5.0 ml 5 1/5 20
Concentrated supernatant, 2.25 mlb 5 1/5 20
aFisher’s exact test (2-tail), control vs. vaccinated P  < .01.
bCulture supernatant concentrated 5.2-fold.
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Figure 1. Serum Leukotoxin-Neutralizing Antibody Titers in Controls or Steers
Vaccinated with 1.0, 2.0, or 5.0 ml Culture Supernatant and 2.25 ml of the
Concentrated (C) Supernatant.  SEM = 1.6, Treatment Effect P<.0l, Week
Effect P<.0l, and Treatment x Week Interaction P<.05.
Figure 2. Serum Leukotoxin-Neutralizing Antibody Titers in Steers that Developed
(N=10) or Did Not Develop (N=15) Liver Abscesses. SEM=1.4, Abscess
Effect P<.05, Week Effect P<.01).
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